185 related articles for article (PubMed ID: 35979889)
21. Effects of dopamine receptor antagonist antipsychotic therapy on blood pressure.
Gonsai NH; Amin VH; Mendpara CG; Speth R; Hale GM
J Clin Pharm Ther; 2018 Feb; 43(1):1-7. PubMed ID: 29119585
[TBL] [Abstract][Full Text] [Related]
22. Combined suppression of the intrarenal and circulating vasoconstrictor renin-ACE-ANG II axis and augmentation of the vasodilator ACE2-ANG 1-7-Mas axis attenuates the systemic hypertension in Ren-2 transgenic rats exposed to chronic hypoxia.
Červenka L; Bíbová J; Husková Z; Vaňourková Z; Kramer HJ; Herget J; Jíchová Š; Sadowski J; Hampl V
Physiol Res; 2015; 64(1):11-24. PubMed ID: 25194129
[TBL] [Abstract][Full Text] [Related]
23. The Renin-Angiotensin and Renal Dopaminergic Systems Interact in Normotensive Humans.
Natarajan AR; Eisner GM; Armando I; Browning S; Pezzullo JC; Rhee L; Dajani M; Carey RM; Jose PA
J Am Soc Nephrol; 2016 Jan; 27(1):265-79. PubMed ID: 25977313
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of renal D5 dopamine receptor ameliorates the hypertension in D3 dopamine receptor-deficient mice.
Wang X; Escano CS; Asico L; Jones JE; Barte A; Lau YS; Jose PA; Armando I
Hypertension; 2013 Aug; 62(2):295-301. PubMed ID: 23753418
[TBL] [Abstract][Full Text] [Related]
25. The dopaminergic system in hypertension.
Zeng C; Zhang M; Asico LD; Eisner GM; Jose PA
Clin Sci (Lond); 2007 Jun; 112(12):583-97. PubMed ID: 17492945
[TBL] [Abstract][Full Text] [Related]
26. High Na intake increases renal angiotensin II levels and reduces expression of the ACE2-AT(2)R-MasR axis in obese Zucker rats.
Samuel P; Ali Q; Sabuhi R; Wu Y; Hussain T
Am J Physiol Renal Physiol; 2012 Aug; 303(3):F412-9. PubMed ID: 22592638
[TBL] [Abstract][Full Text] [Related]
27. Role of angiotensin AT(2) receptors in natriuresis: Intrarenal mechanisms and therapeutic potential.
Carey RM; Padia SH
Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):527-34. PubMed ID: 23336117
[TBL] [Abstract][Full Text] [Related]
28. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.
Mendoza-Torres E; Oyarzún A; Mondaca-Ruff D; Azocar A; Castro PF; Jalil JE; Chiong M; Lavandero S; Ocaranza MP
Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):217-37. PubMed ID: 26275770
[TBL] [Abstract][Full Text] [Related]
29. Recent Advances in Understanding the Molecular Pathophysiology of Angiotensin II Receptors: Lessons From Cell-Selective Receptor Deletion in Mice.
Eguchi S; Sparks MA; Sawada H; Lu HS; Daugherty A; Zhuo JL
Can J Cardiol; 2023 Dec; 39(12):1795-1807. PubMed ID: 37394059
[TBL] [Abstract][Full Text] [Related]
30. The role of the brain renin-angiotensin system in Parkinson´s disease.
Labandeira-Garcia JL; Labandeira CM; Guerra MJ; Rodriguez-Perez AI
Transl Neurodegener; 2024 Apr; 13(1):22. PubMed ID: 38622720
[TBL] [Abstract][Full Text] [Related]
31. The intrarenal blood pressure modulation system is differentially altered after renal denervation guided by different intensities of blood pressure responses.
Lai Y; Zhou H; Chen W; Liu H; Liu G; Xu Y; Du H; Zhang B; Li Y; Woo K; Yin Y
Hypertens Res; 2023 Feb; 46(2):456-467. PubMed ID: 36202981
[TBL] [Abstract][Full Text] [Related]
32. The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases.
Lazartigues E; Feng Y; Lavoie JL
Curr Pharm Des; 2007; 13(12):1231-45. PubMed ID: 17504232
[TBL] [Abstract][Full Text] [Related]
33. Losartan prevents the imbalance between renal dopaminergic and renin angiotensin systems induced by fructose overload. l-Dopa/dopamine index as new potential biomarker of renal dysfunction.
Rukavina Mikusic NL; Kouyoumdzian NM; Uceda A; Del Mauro JS; Pandolfo M; Gironacci MM; Puyó AM; Toblli JE; Fernández BE; Choi MR
Metabolism; 2018 Aug; 85():271-285. PubMed ID: 29727629
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain.
Kumar U; Patel SC
Brain Res; 2007 Feb; 1131(1):187-96. PubMed ID: 17182012
[TBL] [Abstract][Full Text] [Related]
35. Intratubular and intracellular renin-angiotensin system in the kidney: a unifying perspective in blood pressure control.
Li XC; Zhu D; Zheng X; Zhang J; Zhuo JL
Clin Sci (Lond); 2018 Jul; 132(13):1383-1401. PubMed ID: 29986878
[TBL] [Abstract][Full Text] [Related]
36. Chronotherapy with a Renin-angiotensin System Inhibitor Ameliorates Renal Damage by Suppressing Intrarenal Renin-angiotensin System Activation.
Aoki T; Ohashi N; Isobe S; Ishigaki S; Matsuyama T; Sato T; Fujikura T; Kato A; Miyajima H; Yasuda H
Intern Med; 2020; 59(18):2237-2244. PubMed ID: 32938851
[TBL] [Abstract][Full Text] [Related]
37. Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension.
Moon JY
Electrolyte Blood Press; 2013 Dec; 11(2):41-5. PubMed ID: 24627703
[TBL] [Abstract][Full Text] [Related]
38. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney.
Sachetelli S; Liu Q; Zhang SL; Liu F; Hsieh TJ; Brezniceanu ML; Guo DF; Filep JG; Ingelfinger JR; Sigmund CD; Hamet P; Chan JS
Kidney Int; 2006 Mar; 69(6):1016-23. PubMed ID: 16528251
[TBL] [Abstract][Full Text] [Related]
39. Intrarenal mouse renin-angiotensin system during ANG II-induced hypertension and ACE inhibition.
Gonzalez-Villalobos RA; Satou R; Ohashi N; Semprun-Prieto LC; Katsurada A; Kim C; Upchurch GM; Prieto MC; Kobori H; Navar LG
Am J Physiol Renal Physiol; 2010 Jan; 298(1):F150-7. PubMed ID: 19846570
[TBL] [Abstract][Full Text] [Related]
40. Dopaminergic receptor mechanisms modulating the renin-angiotensin system and aldosterone secretion: an overview.
Missale C; Lombardi C; De Cotiis R; Memo M; Carruba MO; Spano PF
J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S29-39. PubMed ID: 2483440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
